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Summary The combination of tamoxifen and transdermal hormone replacement therapy (HRT) may potentially reduce risks and side-effects
of either agent, but an adverse interaction could attenuate their beneficial effects. We assessed the effects of their combination on
cardiovascular risk factors within a prevention trial of tamoxifen. Baseline and 12-month measurements oftotal, low-density lipoprotein (LDL)-
and high-density lipoprotein (HDL)-cholesterol, platelets and white blood cells were obtained in the following four groups: tamoxifen (n =
1117), placebo (n = 1112), tamoxifen and HRT (n = 68), placebo and HRT (n = 87). The analysis was further extended to women who were on
HRT at randomization but discontinued it during the 12-month intervention period (n= 33 on tamoxifen and n = 35 on placebo) and to women
who were not on HRT but started it during intervention (n = 36 in both arms of the study). Compared with small changes in the placebo group,
tamoxifen was associated with changes in total, LDL- and HDL-cholesterol of approximately-90/, -19% and +0.2% in continuous HRT users
compared with -9%/6, -14% and -0.8% in never HRT users. Similarly, there was no interaction on platelet count. In contrast, the decrease in
total and LDL-cholesterol levels induced by tamoxifen was blunted by two-thirds in women who started HRT while on tamoxifen (P= 0.051 for
the interaction term). We conclude that the beneficial effects of tamoxifen on cardiovascular risk factors are unchanged in current HRT users,
whereas they may be attenuated in women who start transdermal HRT while on tamoxifen. Whereas a trial of tamoxifen in women already on
transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity.
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The oestrogen receptor modulator tamoxifen is the standard
endocrine treatment for breast cancer both in the palliative and in
the adjuvant setting (Jaiyesimi et al. 1995). In light ofthe substan-
tial reduction in contralateral breast cancer observed in the world-
wide meta-analysis of adjuvant studies (Early Breast Cancer
Trialists Collaborative Group. 1998). this compound is currently
being tested as a breast cancerpreventive agent in controlled trials.
An interim analysis of the US prevention trial involving 13 388
participants has led to the early closure of the study (Smigel.
1998). It was shown that tamoxifen can approximately halve the
incidence of breast cancer and decrease by 35% the incidence of
osteoporotic bone fractures. Compared with the placebo group.
however. women aced 50 or older receiving tamoxifen had more
than a twofold increased risk of early-stage endometrial cancer
and a threefold increased risk ofpulmonary embolism. Altogether.
these results underline the importance of strategies aimed at
reducing tamoxifen's toxicity while retaining its activity. particu-
larly in post-menopausal women.
Given its pleiotropic pharmacological profile. which partly
reflects the complexity of the oestrogen signalling in the body
(Katzenellebogen. 1996: Yang et al. 1996). tamoxifen has either
Received 3 December 1997
Revised 4 March 1998
Accepted 10 March 1998
Correspondence to: A Decensi. FIRC Chemopreventon Unit at the European
Instie of Oncology. via Riparmonti, 435; 20141 Milan. Italy
agonistic or antagonistic effects on different oestrogen-regulated
targets. For instance. tamoxifen reduces blood lipids and lipo-
proteins (Love et al. 1990: Nayfield. 1995). an effect that has been
associated with a reduction in coronary heart disease in several
adjuvant trials (Rutqvist et al. 1993: McDonald et al. 1995:
Costantino et al. 1997). Like oestrogen replacement therapy.
tamoxifen may sporadically promote endometrial carcinorenesis
(Fisher et al. 1994. Rutqvist et al. 1995) and deep venous throm-
bosis (Fisher et al. 1989: McDonald et al. 1995). Finally. tamoxifen
has shown opposite effects on bone mineral density depending
upon menopausal status (Powles et al. 1996). and its administration
tends to exacerbate menopausal effects such as vasomotor and
urogenital symptoms. particularly in premenopausal women
(Fisher et al. 1989: Love et al. 1991: Powles et al. 1994).
One important issue is the potential benefit ofthe combination of
tamoxifen with hormone replacement therapy (HRT). the use of
which has received increased attention since the introduction ofthe
more physiological and bettertolerated transdermal route ofadmin-
istration (Belchetz. 1994: Nachtigall. 1995). Indeed.HRT could
minimize several disturbing effects of tamoxifen. such as hot
flushes. vaginal dryness or discharge and urinary disturbances.
which may affect long-term compliance (Fisher et al. 1989: Love et
al. 1991: Powles et al. 1994). From another perspective. tamoxifen
could reduce the risk of breast cancer in HRT users (Collaborative
Group on Hormonal Factors in Breast Cancer. 1997: Grodstein et
al. 1997). even though the long-term effects of HRT administered
*SeeAcknowledgements
572Tamoxifen andhormone repkcementtherapy 573
by transdermal route are unknown. In addition to the preventive
context, the combined use of tamoxifen and HRT could increase
both quantity and quality of life in breast cancer survivors. par-
ticularly those who had a premature menopause following
chemotherapy and/or hormonal deprivation (Roy et al, 1996).
It is currently unknown, however, whether the combined use of
tamoxifen and HRT modifies the individual effect of either.
Indeed. a multiplicative effect between the two agents, be it antag-
onistic or synergistic, would have important implications in terms
of biological effects and clinical efficacy. For instance, an antag-
onistic interaction could reduce the efficacy of tamoxifen against
breast cancer or blunt the cardiovascular benefit ofboth agents.
To provide insight into this issue, we studied within a primary
prevention trial the effect of the combination of tamoxifen and
HRT on serum cholesterol, an oestrogen-regulated target and an
established surrogate end point biomarker of coronary heart
disease (Holme, 1990). The effects of tamoxifen and HRT were
also studied on platelet (Plt) and white blood cell (WBC) counts.
inasmuch as both parameters are affected by tamoxifen treatment
(Powles et al, 1994; Lukac et al, 1995) and their levels have been
positively associated with an increased risk of coronary heart
disease in prospective studies (Thaulow et al. 1991; Gillum et al.
1993).
MATERIALS AND METHODS
The present study was performed in the context of the ongoing
breast cancer prevention trial of tamoxifen, in which healthy
women are randomized to tamoxifen 20 mg day p.o. orplacebo for
5 years. A detailed description ofthe trial has been published else-
where (Veronesi et al, 1995). Briefly, eligible women were aged
between 35 and 70, had previous hysterectomy for non-malignant
conditions and no medical history contraindicating tamoxifen use.
The primary end point is breast cancer incidence. Women were
examined at 6-month intervals, whereas fasting blood measure-
ments were obtained at baseline and every 12 months. The study
received Institutional Review Board approval and all subjects
granted written informed consent. Blinding was disclosed after
completion ofthe analysis, following approval by the Data Safety
and Monitoring Committee ofthe trial.
A total of 3479 women were in the breast cancer trial with a
potential follow-up time of at least 12 months. Women who were
recently randomized or who withdrew from the study within 12
months of randomization were not considered. Because of some
leeway in the scheduling of these follow-up visits, women whose
6-month visit did not take place within 4 and 7 months from
randomization and whose 12-month visit took place at more than
15 months from randomization were excluded. No 12-month visit
took place earlier than 10 months from randomization. This was
done to ensure that all women were on the study from approxi-
mately the same length of time. The number of women who did
not meet these criteria was 241. Almost all because the 12-month
visit did not take place.
Based on the information collected at baseline, and at 6 and 12
months, HRT was used at some time during the study by 705 of
3479 women with a possible 12-month follow-up. However, not
all women in the analysis data set were on HRTthroughout the 12-
month period. The information available was HRT use at 0 (base-
line). 6 and 12 months, duration of use, type of HRT. route of
administration and dose.
At baseline 538 women were on HRT. Ofthese. 338 had already
been on transdermal HRT for some time (among which seven were
on combined oestroprogestin treatment and 331 on oestrogen
alone). Of the 200 remaining cases on HRT at baseline. women
were on transdermal oestrogen plus oral progestagen (n =61). oral
conjugated oestrogen (n = 47), oral progestagen (n = 17). intra-
muscular oestroprogestagen (n = 33), oral contraceptives (n = 8)
and other types ofHFI. including unspecified forms (n = 34). For
the transdermal HRT group, dose information was reported in 89%
ofthe cases; ofthese. 75% were treated with a daily dose of50 pg.
22% with 25 jg and 3% with 100 jig ofoestradiol.
The two easiest groups to consider were those women who were
never on HRT (2774 women) and. secondly. those women who
were on HRT throughout the study period (the 'always' group)
(n = 308). The rest used HRT for part of the intervention period
and two other groups were readily identifiable: those women who
were on HRT at baseline but were not on HRT at 12 months (n =
181), and those women who were not on HRT at baseline but were
on HRT at 12 months (n = 135). The remaining 81 women did not
have complete HRT information at all three time points or had
irregular HRT use. Irregular HRT use occurred when a woman was
on HRTat 0 and 12 months but not at6, oroffHRT at 0 and 12 but
on at 6 months, or did not use HRT regularly for long periods.
Women with incomplete orirregular HRT histories were excluded.
In summary, the inclusion criteria were oestrogen-based HRT. the
transdermal route ofadministering HRT and 6- and 12-month visits
within the appropriate time windows. Women with irregular HRT
use were also excluded. In total, 554 women ofthe 3479 with a 12-
month follow-up were excluded from the analysis, leaving 2925
women. Of those women excluded from the analysis, 241 did not
satisfy the time window criteria, 81 had incomplete HRT informa-
tion orirregularHRTuse, 200did nothaveUtansdernal oroestrogen
HRT at baseline, 145 at 6 months and 152 at 12 months. These
numbers add up to more than 554 as many women were excluded
for multiple reasons. Comparison was made initially of 155 women
who were on transdermal HRT throughout the study period (68 on
tamoxifen and 87 ontheplacebo) and 2229 women whowere not on
any form of HRT during the study period (1117 on tamoxifen and
1112 on the placebo). Investigation was then also made of 68
women who were on tansdernal HRT at baseline but not at 12
months (33 on tamoxifen and 35 on placebo) and 72 women who
were not on transdermal HRTat 12 months but had notbeen atbase-
line(36 inboth arms ofthe study). The fourHRTgroups arereferred
to as 'always', 'never', 'yes then off' and 'nothen on'.
Total cholesterol (T-C) and high-density lipoprotein cholesterol
(HDL-C) levels were measured by standard enzymatic methods
using automatic analysers in laboratories participating in national
standardization programmes. Low-density lipoprotein cholesterol
(LDL-C) was determined according to the method of Friedewald
et al (1972). Although this formula implies the measurement of
triglycerides, their values were not recorded in the study data
forms. The T-C/HDL-C ratio was also calculated to better express
the index ofcardiovascular risk (Kinosian et al. 1994).
The main end point of the study was the change in T-C levels
frombaseline to 12 months. Theeffectoftamoxifen andHRTuseon
this change wasestimated by a linearregression model. The interac-
tion between tamoxifen use and HRT use was the main variable to
test Adjustment was made forage, body mass index (BMI; kg m-2),
smoking and initial cholesterol level. The normality assumption of
the change in cholesterol was assessed by normal plots.
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Table 1 Baseline characteristics (mean ± s.d.) in continuous and never HRT
users
Tamoxifen Placebo
Never Alrays Never Always
HRT HRT HRT HRT
Age 52.0+±6.5 50.3+3.5 52.2±6.4 51.7+4.1
(n = 1292) (n = 78) (n = 1292) (n = 95)
Body mass index 25.8 ± 4.3 24.6 ± 3.5 25.7 ± 4.2 24.3 ± 3.8
(kg m-2) (n= 1292) (n=78) (n= 1292) (n= 95)
Smoking status (%o)
Never 63.5 56.4 63.4 63.2
Former 16.4 21.8 17.3 13.7
Current 20.0 21.8 19.4 23.2
(n = 1292) (n = 78) (n = 1292) (n = 95)
T-C (mg dt1) 231 ±43 233 ± 38 233 ±42 230 ± 39
(n = 1287) (n = 78) (n = 1284) (n = 95)
LDL-C(mg d-') 146 _ 42 154 ±36 148 ± 42 142 ± 36
(n = 956) (n = 60) (n = 939) (n = 71)
HDL-C(mg dl-') 57.3 ± 16 59.3 ± 15 58.2 ± 15 62.4+ 15
(n = 1191) (n =69) (n = 1191) (n= 89)
T-CtHDL-C 4.3 +1.4 4.2 1.2 4.3+1.3 3.8 1.0
(n=1189) (n=69) (n=1189) (n=89)
Plt count (x103 mm3) 244 + 55 239 + 53 246 + 56 240 + 51
(n = 1283) (n=77) (n = 1284) (n=95)
WBC count (mm-3) 6493± 1648 6444 1510 6375 ± 1599 6416 1742
(n = 1289) (n=78) (n = 1287) (n=95)
HRT, transdermal hormone replacent therapy; T-C, total choesterol;
LDL-C, low-densty lipoprotein chdesterol; HDL-C, high-density lipoprotein
cholesterol; Plt, platelet; WBC, white blood cell. Differences in the numbers of
observations are due to missing inforrnation on the biomarker at baseline.
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Figure 1 Effect of tamoxifen and baseline cholesterol levels on the change
in total cholesterol over the 12-month intervention period. The solid line is the
estimated change in total cholesterol with baseline total cholesterol in the
placebo group. The dotted line is the corresponding relationship in the
tamoxifen group
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Table 2 Mean (± s.d.) change (12 month baseline) of blood measurements
in continuous and never HRT users
Tamoxffen Placebo
Never Always Never Always
HRT HRT HRT HRT
T-C (mg dl1) -20± 35 -20± 35 1 ± 33 6 25
(n= 1117) (n= 68) (n= 1112) (n= 87)
LDL-C(mg dt-) -21 ± 38 -26 33 -1.0± 36 1 28
(n = 701) (n = 46) (n = 709) (n= 61)
HDL-C (mg dt-) -0.4± 15 -0.3±11 1.0 ± 15 1.2+12
(n=972) (n=58) (n=984) (n=79)
T-C/HDL-C -0.4+1.3 -0.4± 0.9 -0.1 ±1.2 0.0 0.8
(n = 970) (n = 58) (n = 980) (n =79)
Pit count (x103mm-3) -18+ 37 -11 ± 28 -3+ 39 -3 34
(n = 1110) (n = 67) (n = 1104) (n =86)
WBC count (mm-3) -41 ± 1397 -311 ±1106 -42+ 1302 141 1311
(n = 1117) (n = 68) (n = 1112) (n=87)
HRT, transdermal hormone replacement therapy; T-C, total choesterol;
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol: Pft, platelet WBC, white blood cell. Differences in the numbers of
observations are due to missing information on the blomarkers at baseline or
end of study.
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Figure 2 Effect of tamoxfen and age at entry on the change in total
cholesterol over the 12-month intervention period. The solid line is the
estimated change in total choesterol with age in the placebo group. The
dotted line is the corresponding relationship in the tamoxifen group
The principal analysis focused on a comparison ofthose women
who were never on HRT with those women who were on HRT
from baseline to 12 months. A secondary analysis investigated the
effect of tamoxifen among intermittent HRT users. namely.
women who were initially not on HRT but were continuous users
at 12 months or those who were continuous users at baseline but
stopped using HRT within the 12-month follow-up.
RESULTS
The means. s.d. and number of women in each category of HRT
use are presented in Table 1 for the baseline variables. These
figures show that the women in the tamoxifen and placebo arms of
the study are comparable as regards age. BMI. smoking status.
WBC count. Plt count. T-C. LDL-C and T-C/HDL-C ratio as are
the women in the HRT use groups. Baseline WBC and Plt were
lower in older women. higher in women with a larger BMI and
lower among those who were not current smokers. Total choles-
terol was higher in older women (a mean ± s.e. of 241 ± 1.0 mg
dl-' in women aged over 50 years compared with 221 ± 1.1 mg dl-
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Table 3 Mean (± s.d.) change (12 month baseline) of blood measurements
in intermittent HRT users
Tamoxifen Placebo
Yes then No then Yes then No then
off HRT on HRT off HRT on HRT
T-C(mgdh-) -21 ± 34 -6 34 4+42 -4+23
(n=33) (n=36) (n=35) (n=36)
LDL-C (mg d-') -20 ± 42 -6 40 -10 - 35 -8-35
(n = 26) (n=23) (n = 19) (n=27)
HDL-C (mg dt-) -0.0 - 10 -0.4 ± 21 0.6" 14 1.8 + 12
(n=31) (n = 32) (n = 30) (n = 34)
T-C/HDL-C 0.4 1.0 -0.3 ± 1.1 -0.1 ± 1.3 -0.2± 0.9
(n=31) (n = 32) (n= 30) (n=33)
Pft count (x103 mnr-) -16z 33 -24 ± 36 -2 +48 3 30
(n= 34) (n=36) (n=34) (n=37)
WBC count (mm-:) -156" 1210 -6-1183 -255 _1031 139 1031
(n = 34) (n 36) (n = 34) (n=37)
HRT. transderrnal hormone replacement therapy. T-C, total cholesterol;
LDL-C, low-density lipoprotein cholesterol: HDL-C, high-density lipoprotein
cholesterol: Plt. platelet; WBC. white blood cell. Differences in the numbers of
observations are due to missing information on the biowarker at baseline or
end of study.
under 50 years) and lower among those who never smoked (231 ±
0.9 mg d-l in never smokers xs 234 ± 1.3 mr dl-' in current or
former smokers). whereas LDL-C was higher in women over 50
years (155±1.2 mg dl' vs 137 ± 1.2 mg dl-' in women aged under
50 sears). With HDL-C. there was evidence that those on HRT at
baseline had a significantly higher HDL-C than those never on
HRT (P = 0.011. Table 1). Aae and BMI also had an influence on
initial HDL-C. being higher in women aged over 50 years (59 ±
0.4 mg dl-1 compared with women aged under 50 years. 57 + 0.4
mg d1-¼) and lower Smith a higher BMI (61 ± 0.4 mgr dl-l in women
with a BMI greater than 25 kg, m-' compared with 55 ± 0.4 mg dl-].
in BMI less than 25).
The changes in blood measurements over the 12-month inter-
xention period are presented in Table 2. For all cholesterol
measures. there was no influence of HRT on the effect of tam-
oxifen in the chance in the levels over 12 months. At the average
baseline T-C of 231 mg dl- there was a 20.3 + 1.3 ma dl-' mean
reduction in T-C corresponding to a 9± 0.6%e reduction from base-
line with tamoxifen (P < 0.01). but the reduction was the same
irrespective of the HRT status (never or always. P = 0.36 for the
interaction term). In both placebo and tamoxifen groups. the
chance in T-C level was related to baseline T-C level. with a
greater reduction the higher the baseline. Further. the reduction
was greater in the tamoxifen group (P = 0.001) (Figure 1). In the
placebo group there was no effect of age on T-C levels. whereas
the effect oftamoxifen was greater among older women. adjusting
for the effects ofbaseline T-C (P = 0.003) (Figure 2). Adjusting for
baseline T-C and age and their interactions with tamoxifen there
was no effect of BMI on the reduction in T-C (P = 0.50). These
interpretations for T-C apply also to LDL-C and T-C/HDL-C ratio.
With HDL-C there was no evidence of any effect of age. although
there was a negative BMI effect applicable to both tamoxifen and
placebo groups (P = 0.001). Moreover. the modest. albeit signifi-
cant. inhibitory effect of tamoxifen on HDL-C Aas greater among
women with a high HDL-C at baseline (P = 0.012).
With Plt count. there was a significant reduction in the tam-
oxifen group (Table 2). Moreover. there was a slightly greater
reduction in the placebo group with higher BMI in contrast to an
increase in the tamoxifen group (P < 0.01 for the interaction term).
There was a trend to a synergistic interaction between tamoxifen
and HRT use with regard to WBC count: although there was no
chance in WBC count with placebo in the two HRT groups. there
was a greater. albeit modest. reduction if a woman A-as on tam-
oxifen and continuous HRT (P = 0.04. Table 2).
The analysis was further extended to the four groups of inter-
mittent HRT users. whose baseline characteristics. including HRT
dose and blood measurements. were evenly distributed among
groups. Although the HRT doses were similar to those employed
by continuous HRT users (i.e. 70% received 50 og and 30'% 25 ~rg
dax-' oestradiol). similar results were observed only for HDL-C.
WBC and PIt counts but not for T-C and LDL-C levels (Table 3).
Indeed. with T-C there xxas evidence of a borderline antagonist
interaction between tanoxifen and HRT use (P = 0.051). This
manifests itselfin the group that was not on HRT at the beginning
ofthe study but that subsequently went on continuous HRT. In this
group there xxas no evidence ofthe average 20 mg dl-1 reduction in
T-C observed in the other groups (Table 3). A similar feature was
noticed with LDL-C. although its significance xxas reduced xx hen
the variables that influence LDL-C (i.e. age and baseline LDL-C)
were included.
DISCUSSION
On theoretical grounds. the combination of tamoxifen and HRT
could reduce risks and side-effects of either treatment. thus
contributing to post-menopausal women's health in a substantial
way. In fact. although HRT prevents post-menopausal symptoms
and may reduce overall morbidity and mortality by affecting
several important diseases such as coronarx heart disease
(Grodstein et al. 1997). osteoporotic fractures (Riggs et al. 1992)
and colon cancer (Newcomb et al. 1995: Grodstein et al. 1997). the
addition of tamoxifen could prexent the increased risk in breast
cancer incidence and mortalits associated x ith HRT use
(Collaborative Group on Hormonal Factors in Breast Cancer.
1997: Grodstein et al. 1997). Furthermore. HRT use could mini-
mize most tamoxifen side-effects (Fisher et al. 1989. Loxe et al.
1991f. including a progressive rise in endogenous oestrogens in
premenopausal women (Jordan et al. 1991). some of which max
seriously affect treatment compliance. particularly in a preventix e
setting (Powles et al. 1994). Moreover. concomitant HRT
including progestins might even affect the risk of endometrial
cancers during tamoxifen. as the xero large majority ofthese cases
were observed in post-menopausal xxomen (Assikis et al. 1996).
Given the complex pharmacological profile of tamoxifen.
which partly depends on the woman's endocrine milieu (Gallo et
al. 1997). it is. however. important to evaluate the occurrence of
potential interactions between tamoxifen and HRT before consid-
erinc anv clinical trial oftheir combination. Moreover. as HRT use
is allowed in the tamoxifen prevention trials. this study permits a
useful initial assessment ofsuch interactions. The main conclusion
ofourstudy' using this data is that tamoxifen has a similareffect on
cholesterol measures and other cardiovascular risk factors in HRT
users compared with non-users. Specifically. tamoxifen reduced
by approximately 9%. 9%e and 19% the level of T-C. T-C/HDL-C
ratio and LDL-C respectively in continuous HRT users compared
with 9%7. 9% and 14% in nexer HRT users. Also the 0.8%- decline
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in HDL-C induced by tamoxifen was not modified by HRT use.
Similar results were observed on Plt count. whereas a modest
synergistic interaction was observed on WBC count. However, the
clinical significance of this interaction is unclear. Overall, these
results indicate that tamoxifen can be added to transdermal HRT
without modifying their relevant biological effects. thus
supporting the conclusions ofprevious pilot studies in women with
breast cancer (Powles et al. 1993) and in healthy at-risk women
(Chang et al. 1996).
However. in contrast with the findings of the main analysis. a
border-line antagonistic interaction onT-C andT-C/HDL-C and, to a
lesser extent, on LDL-C levels was observed in the group that
started HRT during tamoxifen intervention. Specifically. the 9%
reduction inT-C and T-C/HDL-C levels in the tamoxifen group was
blunted by two-thirds after the initiation of HRT. Although this
conclusion should be treated with caution, given the limited number
of cases and the borderline significance level, the observation that
the number ofwomen starting HRT during intervention was similar
in the tamoxifen and placebo arms ofthe study seems to exclude the
bias of an uneven HRT prescription. Moreover. the finding was not
due to a dose dependence ofthe interaction, as oestadiol doses were
similar in continuous and intermittent HRT users, nor to a higher
rate of withdrawal from tamoxifen in the women who started HRT
during the trial (not shown). Also. although this analysis may not be
robust in view ofthe small numbers in this arm ofour observational
study, we have doubled the number of subjects in comparison with
the previous study by Chang et al (1996). where the same pattem of
response is also evident among women prescribed HRT while
recently given tamoxifen.
Another important finding ofour study is the observation that the
inhibitory effect of tamoxifen on cholesterol measures was modi-
fied by age and baseline cholesterol levels, a greater reduction
being observed in older women and in women with higher baseline
concentrations. This would imply that the magnitude ofthe preven-
tive efficacy of tamoxifen on coronary heart disease will be more
pronounced in these higher risk categories, thus achieving a
substantial reduction in terms of cardiovascular events (Holme.
1990; Smith et al. 1993). Moreover, the significant decrease in Plt
count, another factor associated with cardiovascular morbidity
(Thaulow et al, 1991; Handin. 1996). might further contribute to the
protective effect of tamoxifen. In this regard. the expected reduc-
tion in cardiovascular events by tamoxifen based on its effects on
the lipid profile is approximately 20% (Costantino et al. 1997). an
estimation that will be verified in the ongoing prevention trials.
Admittedly. there are some limitations to our study. Firstly.
women on HRT represent a subgroup in the trial and were not
randomized to HRT use. Consequently. we cannot exclude the
possibility that the population receiving HRT was selectedbased on
a higher cholesterol level than non-users, although the mild modu-
lation of cholesterol measures observed in de novo HRT users in
the placebo group seems todiscount this possibility. Secondly, lipid
measurements and blood cell counts were not centralized, although
these measures are obtained by routine standard techniques and
there is no reason to believe that inter-laboratory-variation was
unevenly distributed among the groups. Finally, the spectrum ofthe
end points analysed in our study was relatively limited, as other
important oestrogenic markers such as the haemostasis profile,
bone mass and mammographic density were not measured-
Against these limitations, it is important to consider that our
results were obtained in a selected population, namely hysterec-
tomized women, where the incidence ofcardiovascularrisk factors
is likely to be higher than in the general population (Rosemberg et
al. 1981). Indeed. 47% of the women in the study were aged over
50 years and 37% of those under the age of 50 had a premature
menopause as a result of a bilateral oophorectomy. In addition. the
lack ofprogestin in virtually all HRT users should be considered in
the evaluation of cholesterol results, although oral progestins such
as medroxyprogesterone acetate do not seem to attenuate the
effects of oestrogen replacement therapy both on cardiovascular
risk factors (The writing group for the PEPI trial. 1995) and events
(Grodstein et al. 1996. 1997). Finally, our conclusions are
restricted to the use oftransdermal HRT and may not be applicable
to oral HRT. In fact our data confirm the limited effect exerted by
transdermal HRT on the lipid profile that has already been
observed in most previous studies (Chetkowsky et al. 1986: Colvin
et al, 1990: Walsh et al. 1994). In contrast, the four to fivefold
increased oestrogen concentration reached in the hepatic circula-
tion by oral HRT leads to profound lipid and protein changes
(Belchetz. 1994). which are more likely to modify tamoxifen
effects. Differences in hepatic synthesis include a higher oestra-
diol-oestrone ratio (Van Erpecum et al. 1991: Walsh et al. 1994). a
lack of induction of sex-hormone-binding globulin (Chetkowsky
et al, 1986, Van Erpecum et al. 1991: Slowinska-Srzednicka et al.
1992) and a trend towards elevated insulin-like growth factor I
concentrations (Weissberger et al. 1991: Slowinska-Srzednicka et
al. 1992) with the transdermal route of administration. As all these
effects may exert a higher proliferative stimulation on the breast
than oral HRT. the rationale for adding tamoxifen to transdermal
HRT is further supported.
In conclusion, our results show no modification ofthe inhibitory
effect of tarnoxifen on cardiovascular risk factors in women
already on transdermal HRT. In contrast. a borderline adverse
interaction on cholesterol measures was observed in those women
who initiated HRT while already on tamoxifen intervention. The
reduction of cholesterol by tamoxifen was greater with increasing
age and higher baseline concentrations. Whereas our results
provide the background for a trial of tamoxifen in women who
already receive transdermal HRT. they suggest that HRT prescrip-
tion during tamoxifen may attenuate its activity.
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